ESTRO 2026 has drawn to a close — and for S.I.T., this year’s edition reinforced a clear vision: FLASH Radiotherapy is no longer a horizon, but a direction. Once again, ESTRO – European Society for Radiotherapy and Oncology, the leading European congress dedicated to radiotherapy and oncology, brought together professionals, researchers, companies and clinical centres from all over the world.
In this international setting, S.I.T. shared its technological approach towards FLASH: not as uncharted territory, but as the natural evolution of a well-established path built through years of experience in IOeRT.
A journey that starts from the clinical experience gained with LIAC HWL (linear accelerator for intraoperative radiotherapy – IORT), continues through the development of Treatment Planning Systems (TPS), and extends to ElectronFlash, S.I.T. dedicated platform designed for ultra-high dose rate research.
Meetings and Discussions
S.I.T.’s presence at ESTRO 2026 went beyond the presentation of its devices and technologies. The congress represented an important opportunity for sharing ideas, scientific dialogue and developing new relationships within the advanced radiotherapy landscape, through meetings and discussions with professionals, partners and international stakeholders.
One of the most significant moments was the exchange with university physicians and professionals from different countries who showed interest in the technological approach developed by S.I.T. — particularly around the question of clinical readiness and how established IORT expertise translates into the FLASH context
We would also like to extend a heartfelt thank you to our distributors, who accompanied potential clients to our booth, focusing the discussion on the applications of LIAC HWL in the field of IORT.
Another interesting element that emerged during the congress was the interest shown by international distributors and new potential partners, who visited the booth to learn more about S.I.T.’s technological positioning and explore possible future collaborations. A concrete sign of the growing international attention towards the technologies developed by the company.
Chc FlashPrime: Growing Interest in an Upcoming Technology
A recurring topic throughout the conversations was Chc FlashPrime, the device developed by S.I.T. for FLASH Radiotherapy, currently expected to enter the market between the end of 2026 and the beginning of 2027.
The interest collected was not limited to technical and technological aspects but also focused on the clinical and practical perspectives of FLASH Radiotherapy and its potential impact on future clinical workflows.
Many visitors were interested in learning more about S.I.T.’s vision for the future of ultra-high dose rate and understanding how the experience gained over the years in IORT, dosimetry and beam control now represents the foundation for approaching the evolution towards FLASH technologies with a progressive and structured approach.
ESTRO 2026 in One Word: Insightful
The opportunity to engage directly with professionals involved daily in clinical practice and research proved to be particularly meaningful, allowing S.I.T. to collect feedback, observations and different perspectives on the future of oncological radiotherapy.
For S.I.T., ESTRO continues to represent a place for dialogue and shared growth, where technology, clinical experience and research can come together to foster new connections and potential international collaborations.
The company would like to thank all professionals, distributors, partners and visitors who stopped by the booth during the congress, contributing with their interest and discussions to make this experience particularly stimulating and full of future perspectives.
As the Chc FlashPrime platform moves closer to market, S.I.T. remains committed to one belief: that the future of FLASH radiotherapy is built on experience, not improvisation.
